Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IPB-tre is a dietary supplement developed by Bio-STILOGIT Pharmaceuticals, primarily marketed in Italy for the management of symptoms associated with benign prostatic hyperplasia (BPH). It is a combination product containing botanical extracts, typically including *Serenoa repens* (saw palmetto), *Urtica dioica* (stinging nettle), and *Boswellia serrata*. These ingredients are traditionally utilized for their anti-inflammatory and anti-androgenic properties to support prostate health and urinary function. As a retail consumer product, it is sold directly to consumers and does not have formal clinical trial phases or a single molecular target disclosed in a pharmaceutical pipeline context.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IPB-tre.